Emerging studies highlight high on-treatment of platelet reactivity (HTPR) as a major
hindrance to the secondary prevention of cardiovascular ischemic events. The aim of this …

Background The prevalence of ex vivo 'high on-treatment platelet reactivity (HTPR)'and its
relationship with recurrent vascular events/outcomes in patients with ischaemic …

Objective To investigate the prognostic value of aspirin reaction units (ARU) in a 3-month
follow-up study in a cohort of Chinese patients with first-ever ischemic stroke. Methods …

Background There have been conflicting results for the association between
cyclooxygenase (COX) genetic variants and aspirin resistance (AR). The aim of this study …

To explore the correlation of aspirin resistance (AR) with clinical stroke severity and infarct
volume using diffusion-weighted imaging (DWI) in 224 Chinese ischemic stroke patients …

Background: The aim of this prospective, a three-year follow-up study, was to establish the
role of high on-treatment platelet reactivity (HTPR) in predicting the recurrence of vascular …

Background The effect of genetic variants on aspirin resistance (AR) remains controversial.
We sought to assess the association of genetic variants with AR and early clinical outcomes …

Early assessment of thrombogenicity and antithrombotic drug effects may be important for
therapeutic decision making in patients presenting with acute stroke. In this prospective …

Background We sought to investigate the clinical implications of platelet reactivity to aspirin
and the variability in the platelet reactivity to aspirin during acute periods for the risk of …

Objectives High on‐treatment platelet reactivity (HTPR) determined by platelet function
assays is present in certain patients with ischemic stroke or transient ischemic attack (TIA) …